官方服务：
资源简介：
FCHL-statin-treatment
应用场景：
创建时间：
2013-06-01
相关数据集
Data_Sheet_1_The impact of HMG-CoA reductase inhibitors use on the clinical outcomes in critically ill patients with COVID-19: A multicenter, cohort study.docx
BackgroundThe cardiovascular complications of Coronavirus Disease 2019 (COVID-19) may be attributed to the hyperinflammatory state leading to increased mortality in patients with COVID-19. HMG-CoA Red
NIAID Data Ecosystem20
Risk of breast cancer death by amount, duration and intensity of post-diagnostic statin use compared to non-users in a cohort of all breast cancer cases diagnosed in Finland during 1995–2003.
aCalculated with Cox regression model adjusted for age, tumor stage and morphology, treatment selection and pre-diagnostic statin use.DDD = Defined Daily Dose.Risk of breast cancer death by amount, du
Figshare2015-12-02 更新00
Efficacy and Safety Study of Pitavastatin Compared to atoRvastatin in Type 2 dIabeTes Mellitus With Hypercholesterolemia
A randomized, open label, dose titration study to evaluate the efficacy and safety of Pitavastatin compared to atorvastatin in Type 2 Diabetes Mellitus with hypercholesterolemia
DataMed00
Table_5_The effect of various types and doses of statins on C-reactive protein levels in patients with dyslipidemia or coronary heart disease: A systematic review and network meta-analysis.docx
ObjectiveThe objective of this study was to measure the efficacy of various types and dosages of statins on C-reactive protein (CRP) levels in patients with dyslipidemia or coronary heart disease. Met
NIAID Data Ecosystem10
Adverse reactions.
BackgroundAlthough the current guideline recommends the use of high-intensity statin to reduce the low-density lipoprotein cholesterol (LDL-C) level by 50% in patients with baseline value of ≥ 190 mg/
Figshare2023-06-12 更新00
